Genetically Modified T-Cells in Treating Patients With Advanced Non-Hodgkin's Lymphoma

Inclusion Criteria

• PROCUREMENT INCLUSION CRITERIA * Diagnosis of recurrent aggressive or indolent B-cell lymphoma or CLL, or newly diagnosed patients unable to receive or complete standard therapy OR diagnosis of relapsed/refractory aggressive B-cell lymphoma with a treatment plan that will include high dose therapy and autologous stem cell transplantation * CD19-positive tumor (result can be pending at this time) * Hemoglobin (Hgb) > 8.0 * If pheresis required to collect blood: ** Creatinine < 1.5 × upper limit normal ** Aspartate aminotransferase (AST) < 1.5 × upper limit normal ** Prothrombin time (PT) and activated partial thromboplastin time (APTT) < 1.5 × upper limit normal * Informed consent explained to, understood by and signed by patient/guardian (and donor, where applicable); patient/guardian given copy of informed consent
• TREATMENT INCLUSION CRITERIA:
• Diagnosis of recurrent aggressive or indolent B-cell lymphoma or CLL, or newly diagnosed patients unable to receive or complete standard therapy OR diagnosis of relapsed/refractory aggressive B-cell lymphoma with a treatment plan that will include high dose therapy and autologous stem cell transplantation
• CD19-positive tumor
• Absolute neutrophil count (ANC) > 500
• Hgb > 8.0
• Bilirubin less than 3 times the upper limit of normal
• AST less than 5 times the upper limit of normal
• Serum creatinine less than 3 times the upper limit of normal
• Pulse oximetry of > 90% on room air
• Karnofsky or Lansky score of > 60%
• Recovered from acute toxic effects of prior chemotherapy at least one week before entering this study
• Available autologous or syngeneic activated peripheral blood T cell products (CD28zeta and CD28/CD137zeta) with >= 15% expression of CD19.CAR determined by flow cytometry
• Life expectancy of greater than 12 weeks
• Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded; the male partner should use a condom
• Patients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects; patients or their guardians will be given a copy of the consent form

Exclusion Criteria

• PROCUREMENT EXCLUSION CRITERA * Active infection requiring antibiotics * No history of other cancer (except non-melanoma skin cancer or in situ breast cancer or cervix cancer) unless the tumor was successfully treated with curative intent at least 2 years before trial entry
• TREATMENT EXCLUSION CRITERIA:
• Currently receiving any investigational agents or received any tumor vaccines within the previous 6 weeks
• History of hypersensitivity reactions to murine protein-containing products
• Pregnant or lactating
• Tumor in a location where enlargement could cause airway obstruction
• Active infection with human immunodeficiency virus (HIV) or human T-cell lymphotropic virus (HTLV)